The US pharmaceutical company Johnson and Johnson has developed a vaccine that has shown a strong immune response in its early trials with a single dose in response to the novel coronavirus. The information was published at an interim report on the medical website medRxiv.
The report further said that the safety profile and immunogenicity after only a single dose are supportive for further clinical development of vaccine Ad26, COV2.S can be potentially protective against the coronavirus.
Meanwhile, ahead of the presidential election on November 3, US President Donald Trump promised that over 100 million doses of COVID-19 vaccine will be distributed throughout the United States by the end of 2020. However, several leaders and democrats have accused Trump of trying to fast-track the vaccine approval process in order to get one ahead of the most awaited elections.